Buprenorphine as an analgesic and opioid dependence treatment has a 'ceiling effect' for respiratory depression but not for analgesia. This is BEST explained by:

• A Buprenorphine's partial agonism at mu-opioid receptor reaches maximum receptor activation at high doses for analgesia but cannot further activate respiratory centres
• B As a mu partial agonist, buprenorphine's intrinsic activity is sufficient for analgesia (mu receptor density in pain pathways is high) but below the threshold for respiratory depression (requiring full activation) ✓
• C Buprenorphine's kappa antagonism prevents respiratory depression while allowing mu-mediated analgesia
• D Buprenorphine's slow receptor dissociation rate (long receptor occupancy) ensures sustained analgesia without respiratory depression

Explanation

Buprenorphine is a partial agonist at mu-opioid receptors with high receptor affinity but low intrinsic activity (efficacy ~25–40%). Analgesia requires relatively modest receptor activation (analgesic pathways in spinal cord and PAG have sufficient receptor reserve), so buprenorphine's partial efficacy is adequate. Respiratory depression, however, is mediated in the pre-Bötzinger complex where achieving full opioid-receptor activation is required for maximal respiratory suppression. The partial agonism means a dose plateau (ceiling) is reached beyond which no further respiratory depression occurs. The kappa antagonism (option C) contributes to its attenuated euphoria, not the respiratory ceiling.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.